Modality
mRNA
MOA
AuroraAi
Target
AHR
Pathway
STING
Thymoma
Development Pipeline
Preclinical
~Jan 2021
→ ~Apr 2022
Phase 1
Jul 2022
→ Apr 2029
Phase 1Current
NCT06578257
1,333 pts·Thymoma
2022-07→2029-04·Recruiting
1,333 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2029-04-143.0y awayInterim· Thymoma
Trial Timeline
Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2
P1
Recruit…
Catalysts
Interim
2029-04-14 · 3.0y away
Thymoma
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06578257 | Phase 1 | Thymoma | Recruiting | 1333 | PFS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-2901 | Pfizer | Phase 2 | AHR | |
| Voxarasimod | Merck & Co | Phase 1/2 | CD19 | |
| AZN-1715 | AstraZeneca | Phase 3 | AHR | |
| TAK-5300 | Takeda | Phase 1 | SMN2 | |
| BAY-6520 | Bayer | Phase 2 | AHR | |
| DSN-791 | Daiichi Sankyo | NDA/BLA | Aβ | |
| REG-861 | Regeneron | Phase 2 | PARP | |
| MRN-5715 | Moderna | NDA/BLA | CDK4/6 | |
| BGN-6990 | BeiGene | Phase 2/3 | BCMA | |
| Semasacituzumab | Jazz Pharma | Phase 2 | AHR |